AU2024313859A1 - Novel bispecific fusion protein and use thereof - Google Patents

Novel bispecific fusion protein and use thereof

Info

Publication number
AU2024313859A1
AU2024313859A1 AU2024313859A AU2024313859A AU2024313859A1 AU 2024313859 A1 AU2024313859 A1 AU 2024313859A1 AU 2024313859 A AU2024313859 A AU 2024313859A AU 2024313859 A AU2024313859 A AU 2024313859A AU 2024313859 A1 AU2024313859 A1 AU 2024313859A1
Authority
AU
Australia
Prior art keywords
glp
fusion protein
bispecific fusion
analogue
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024313859A
Other languages
English (en)
Inventor
Jaeil ROH
Young Chul Sung
Sang In YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Slbigen Inc
Original Assignee
Slbigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Slbigen Inc filed Critical Slbigen Inc
Publication of AU2024313859A1 publication Critical patent/AU2024313859A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2024313859A 2023-06-22 2024-06-21 Novel bispecific fusion protein and use thereof Pending AU2024313859A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR2023008718 2023-06-22
KRPCT/KR2023/008718 2023-06-22
PCT/KR2024/008655 WO2024263005A1 (ko) 2023-06-22 2024-06-21 신규 이중 특이성 융합단백질 및 그의 용도

Publications (1)

Publication Number Publication Date
AU2024313859A1 true AU2024313859A1 (en) 2026-01-15

Family

ID=93935935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024313859A Pending AU2024313859A1 (en) 2023-06-22 2024-06-21 Novel bispecific fusion protein and use thereof

Country Status (5)

Country Link
EP (1) EP4733314A1 (https=)
JP (1) JP2026507086A (https=)
CN (1) CN121358758A (https=)
AU (1) AU2024313859A1 (https=)
WO (1) WO2024263005A1 (https=)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070115947A (ko) * 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
ES2623925T3 (es) 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
KR101442254B1 (ko) 2008-02-22 2014-09-24 포항공과대학교 산학협력단 최적의 진핵 세포 발현 벡터의 개발
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
KR102349717B1 (ko) * 2020-03-12 2022-01-11 주식회사 에스엘메타젠 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
US20240368239A1 (en) * 2020-03-12 2024-11-07 Sl Metagen Novel bispecific protein and use thereof

Also Published As

Publication number Publication date
WO2024263005A1 (ko) 2024-12-26
CN121358758A (zh) 2026-01-16
JP2026507086A (ja) 2026-02-27
EP4733314A1 (en) 2026-04-29

Similar Documents

Publication Publication Date Title
US10711051B2 (en) Multivalent heteromultimer scaffold design and constructs
JP6722175B2 (ja) 代謝障害を処置するための組成物及びその使用方法
KR20240078629A (ko) 이중 작용 단백질 및 이를 포함하는 약학적 조성물
US10358479B2 (en) Multivalent heteromultimer scaffold design and constructs
CN115304666B (zh) 一种治疗代谢疾病的胰高血糖素类似物
JP7014515B2 (ja) 持続型インスリンアナログ結合体及び持続型インスリン分泌ペプチド結合体を含む糖尿病治療用組成物
JP7268202B2 (ja) 代謝性疾患を治療するための融合タンパク質
KR102692516B1 (ko) 융합 단백질을 포함하는 간염증, 간섬유화 및 간경화 예방 또는 치료용 약학적 조성물
US20220023388A1 (en) Fusion proteins with extended serum half life
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
US20240254187A1 (en) Dual-function protein for lipid and blood glucose regulation
KR102826981B1 (ko) 신규 이중 특이성 단백질 및 그의 용도
JP2024519950A (ja) Ｇｄｆ１５変異体及びｇｌｐ－１受容体作動薬を含む併用投与用組成物
MX2012005912A (es) Conjugado de polipeptido.
KR20090077935A (ko) 내당능 장애 관련 증상을 예방하거나 치료하기 위한 인간 ｅｐｏ 수용체 작용제, 조성물, 방법 및 용도
AU2024313859A1 (en) Novel bispecific fusion protein and use thereof
KR102349717B1 (ko) 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
CA3085252A1 (en) Dual-function protein for lipid and blood glucose regulation
WO2026037938A1 (en) Fusion proteins comprising a glp-1 receptor agonist and a myostatin pathway inhibitor
WO2025247305A1 (zh) 融合蛋白分子及其应用
WO2025247309A1 (zh) 融合蛋白分子及其应用
CA2950266C (en) Composition for treating diabetes, comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate
KR20210141406A (ko) 신규 재조합 융합단백질 및 그의 용도
CN120530128A (zh) 双功能蛋白及其用途
EP2906237A2 (en) Multivalent heteromultimer scaffold design an constructs